POST HEPATITIS B VACCINATION SEROPROTECTION

RATE AMONG HEALTHCARE WORKERS AT THE UHS

AND CCMH.

BY
BAYUKO GAFARU & MABEL NUAMAH

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

1 04/21/2021
 THE PROBLEM

Hepatitis B Infection is one of the most highly prevalent infections

that causes significant morbidity and mortality, across the globe.
Healthcare Workers (HCWs) represent one of the largest groups
that stands high risk for HBV infection worldwide. They are at
four-time greater risk compared to the general adult population.
Interventions made by The CDC in 1997 to vaccinate all healthcare
workers has significantly decreased the seroprevalence of HBV
infection in this target group globally.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

2 04/21/2021
 THE PROBLEM (CONT..)

However, in some HCWs (non-responders), there is

vaccine failure. Approximately 5-­10% of those
vaccinated against HBV fail to respond with the
development of antibody.
Moreover, Anti-HBs titres decrease over time.
HCWs who do not respond to the vaccine are still at
risk of HBV infection.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS 3 04/21/2021
 THE AIM AND OBJECTIVES OF THE
STUDY
AIM
This study aims to evaluate the seroconversion of Hepatitis B
vaccine among healthcare workers (HCWs) at the UHS And CCMH,
Cape Coast, Ghana.
OBJECTIVES
1. To determine the seroprevalence of HBsAg among the study
population.
2. To measure the sero-protection rate and Anti-HBs titres among HBV
vaccinated HCWs.
3. To identify the factors associated with sero-protection and
seroconversion among HCWs after HBV vaccination.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

4 04/21/2021
 THE HYPOTHESIS

There will be a significant seroprevalence of HBV among HCWs who fail to

respond to the vaccine.

 The serostatus of those who vaccinated close to two decades ago will have
their anti-Hbs titre bellow the protective levels.

In Ghana, there is no data on the assessment of protective levels of anti-HBs

among vaccine recipients. What proportion of our HCWs failed to respond
to the vaccine?

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

5 04/21/2021
 MATERIALS AND METHODS

Study design: Hospital-based analytical cross-sectional study will be

conducted among healthcare workers between November 2018 and May 2019.

Study site: University Health Service and Cape Coast Metropolitan Hospital.

Study population: The study population encapsulate all HCWs in the hospital,
including;
 Doctors
 Nurses of all category
 Laboratory and pharmacy staff
 Mortuary staff
 Cleaners and other category of staff work in the hospital and come into contact with patients.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

6 04/21/2021
 MATERIALS AND METHOD

Sample size
 The prevalence of HBV vaccination among health workers is estimated
to be 50%.
 A minimum of 5% of the health workers in this study are assumed not
to be seroprotected (or seroconverted).
 So, with a power of 80% and significance level of 0.05, 294 health
workers are required to detect a 5% decrease in seroprotection.
 Making a provision of 10% for contingencies, a sample size of 300
health workers will be considered for this study.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWs 7 04/21/2021
 MATERIALS AND METHODS (CONT..)

Serological Analysis

HBsAg Screaning: using the immunochromatographic test strip assay kit

(Guangzhou Wondfo Biotech Co., Ltd.,No. 8 Lizhishan Road, Science City,Luogang
District, 510663, Guangzhou P.R, China) per the manufacturer’s instructions.

HBsAb Quantification: this would be done using the Enzyme-linked Immunosobent

Assay (ELISA) technique which involve the use of HBsAb ELISA Kit (Fortress
Diagnostics Limited, United 2C Antrim Technology Park, Belfast Road, Antrim,
Northern Ireland, United Kingdom),according to the manufacturer’s instructions.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

8 04/21/2021
 DATA MANAGEMENT AND WORK PLAN/TIMELINE
ANALYSIS
PERIOD ACTIVITY
Data Management And Analysis

 Data analysis will be done with Stata version 14.0. 1st Nov-30th Nov 2018 Data collection
 The data analysis will involve two parts.
1st Dec 2018-31st Jan 2019 Break
1. Descriptive statistics (the characteristics of study
responders) .
1st Feb 2019-28th Feb 2019 Data collection continues
2. Inferencial statatistics (the seroconversion status) and complete.

Expected Outcome 1st mar 2019- 15th Apr 2019 Lab work.
 It is expected that, out of the total number of health
16th Apr 2019- 30th Apr 2019 Data analysis, discussion
care workers evaluated at the Cape Coast of results and drawing
conclusions.
Metropolitan Hospital, about 90 percent of them will
have seroprotection against Hepatitis B Virus. 1st May 2019-31st May 2019 Finishing touches,
corrections and
submission

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

9 04/21/2021
 FINANCE
CONSUMABLE QUANTITY UNIT COST/GHȼ TOTAL COST/GHȼ
EDTA tubes 4 pcs 45.00 180.00
Hand gloves 4 boxes 20.00 80.00
Note book 2 book 15.00 30.00
Printing 350 pages 0.20 70.00
Transportation 45 complete trips 4.00 180.00
Syringes 4 boxes 25.00 100.00
Cotton ball 2 rolls 20.00 40.00
Alcohol(methanol) 1000ml 50.00 50.00
Tourniquet     20.00
SUBTOTAL COST     750.00

REAGENT QUANTITY
UNIT COST/GHȼ TOTAL COST/GHȼ

Combo kit(HBsAg) 4 200.00 800.00

ELISA kit 4 2,000.00 8,000.00
SUBTOTAL 8,800.00
OVERAL TOTAL 9,550.00
THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS
10 04/21/2021
 REFERENCES

1. Schweitzer, A., et al., Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic
review of data published between 1965 and 2013. Lancet, 2015. 386: p. 1546–55.
2. WHO. Hepatitis B. 2016 [cited 2016 13th April]; Available from:
http://www.who.int/mediacentre/factsheets/fs204/en/(2016).
3. Ofori-Asenso, R. and A.A. Agyeman, Hepatitis B in Ghana: a systematic review & meta-analysis of prevalence
studies (1995-2015). 2016. 16: p. 130.
4. Roy-Biswas, R.S., M.N. Karim, and B. Bhattacharjee, Hepatitis B virus infection and vaccination status among
health care workers of a tertiary care hospital in Bangladesh. J Sci Soc, 2015. 42: p. 176-9.
5. CDC, Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization
Practices, MMWR. 2011. p. 1–48.
6. Gilca, V., et al., Antibody and immune memory persistence after vaccination of preadolescents with low doses of
recombinant hepatitis B vaccine. Human Vaccines, 2014. 6(2): p. 212–8.
7. Ayerbe, M.C., A. Perez-Rivilla, and I. group, Assessment of longterm efficacy of hepatitis B vaccine. Eur J
Epidemiol, 2001. 17(2): p. 150–6.
8. Chathuranga, L.S., F. Noordeen, and A.M. Abeykoon, Immune response to hepatitis B vaccine in a group of
health care workers in Sri Lanka. Int J Infect Dis, 2013. 17: p. 078­-1079.

THE SEROCONVERSION OF HBV VACCINE AMONG UHS & CCMH HCWS

11 04/21/2021